Burimamide

Burimamide
Names
	IUPAC name 1-[4-(1H-imidazol-5-yl)butyl]-3-methylthiourea
Identifiers
CAS Number	34970-69-9 ;
3D model (JSmol)	Interactive image;
ChEMBL	ChEMBL12160 ;
ChemSpider	2297780 ;
KEGG	C07448 ;
PubChem CID	3032915;
UNII	TN5A4OD2TV ;
CompTox Dashboard (EPA)	DTXSID00188519 ;
	InChI InChI=1S/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14) Key: HXRBAVXGYZUSED-UHFFFAOYSA-N ; InChI=1/C9H16N4S/c1-10-9(14)12-5-3-2-4-8-6-11-7-13-8/h6-7H,2-5H2,1H3,(H,11,13)(H2,10,12,14) Key: HXRBAVXGYZUSED-UHFFFAOYAJ;
	SMILES CNC(=S)NCCCCc1c[nH]cn1;
Properties
Chemical formula	C9H16N4S
Molar mass	212.32 g/mol
	Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). verify (what is ?) Infobox references

Burimamide is an antagonist at the H₂ and H₃ histamine receptors. At physiological pH, it is largely inactive as an H₂ antagonist, but its H₃ affinity is 100x higher. It is a thiourea derivative.

Burimamide was first developed by scientists at Smith, Kline & French (SK&F; now GlaxoSmithKline) in their intent to develop a histamine antagonist for the treatment of peptic ulcers. The discovery of burimamide ultimately led to the development of cimetidine (Tagamet).